Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of XNW5004 in the Treatment of Patients With Relapsed or Refractory Follicular Lymphoma (EZH2 Wild-type)

NCT07545603 is registered in ClinicalTrials.gov with Evopoint Biosciences Inc. as lead sponsor.

NCT NCT07545603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07545603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of XNW5004 in the Treatment of Patients With Relapsed or Refractory Follicular Lymphoma (EZH2 Wild-type)
Lead sponsor
Evopoint Biosciences Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
February 14, 2026
Completion date
December 31, 2028
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma grade 3a, follicular lymphoma, grade 1, follicular lymphoma, grade 2, follicular lymphoma, grade 3